65,437 trials
Mild Cognitive Impairment · Prodromal Alzheimer's Disease
Primary: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline — 1.1; .9 score on a scale
Common Cold
Primary: Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score — 75.8; -1.5; -15.4; -27.3 score on a scale — p=0.2968
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Midazolam and 1-hydroxymidazolam — 22.0; 18.5; 9.92; 7.97 ng/mL
HIV Infections · Non-Alcoholic Fatty Liver Disease
Primary: Change (Absolute) in IHTG (%) — -4.24 IHTG % — p=<0.001
Systematic Review
Primary: Confidence in the Results of the Systematic Review — 4.6; 4.4 score on a scale — p=0.5
Diffuse Large B-Cell Lymphoma · B-cell Non-Hodgkin's Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 16; 8; 12; 32 Participants
Breast Cancer
Primary: ORR 24 — 71.1; 70.9 percentage of responders
Chemotherapy-induced Neutropenia
Primary: DSN — 0.15; 0.36; 0.43; 0.29 days
Suicide
Primary: Percentage of Eligible Youth-Parent Dyads Who Agree to Participate in the Study, — 125 Parent-youth dyads
Knee Osteoarthritis
Primary: University of California, Los Angeles (UCLA) Activity Score — 5.4 score on a scale
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
Oxygen Toxicity
Primary: Change in Percentage Predicted Forced Expiratory Volume in One Second (FEV1%) — 88.0; 85.9; 87.4; 84.6 Percentage of FEV1
Chronic Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Reduction in Bladder Medication — 19; 15 Participants
Obesity · Overweight
Primary: Percent Change From Baseline in Body Weight — 3.3; -21.1 Percent change — p=<0.001
Tuberous Sclerosis Complex · Epilepsy
Primary: Safety - Adverse Events — 40 percentage of participants